Logo image of TVRD

TVARDI THERAPEUTICS INC (TVRD) Stock Overview

NASDAQ:TVRD - US1407553072 - Common Stock

28.76 USD
-0.82 (-2.77%)
Last: 9/3/2025, 4:30:01 PM

TVRD Key Statistics, Chart & Performance

Key Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap269.77M
Shares9.38M
Float5.33M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-78.48
PEN/A
Fwd PEN/A
Earnings (Next)11-12 2025-11-12/amc
IPO01-31 2014-01-31
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


TVRD short term performance overview.The bars show the price performance of TVRD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10 15

TVRD long term performance overview.The bars show the price performance of TVRD in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of TVRD is 28.76 USD. In the past month the price increased by 10.66%.

TVARDI THERAPEUTICS INC / TVRD Daily stock chart

TVRD Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 45.69 698.33B
JNJ JOHNSON & JOHNSON 17.8 428.68B
AZN ASTRAZENECA PLC-SPONS ADR 18.49 254.58B
NVO NOVO-NORDISK A/S-SPONS ADR 14.55 252.12B
NVS NOVARTIS AG-SPONSORED ADR 14.49 248.23B
MRK MERCK & CO. INC. 10.93 210.26B
PFE PFIZER INC 7.31 140.94B
SNY SANOFI-ADR 11.29 121.68B
BMY BRISTOL-MYERS SQUIBB CO 7.06 96.68B
GSK GSK PLC-SPON ADR 8.77 79.29B
ZTS ZOETIS INC 24.51 67.55B
TAK TAKEDA PHARMACEUTIC-SP ADR 52.24 47.85B

About TVRD

Company Profile

TVRD logo image Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company is headquartered in Sugar Land, Texas and currently employs 10 full-time employees. The company went IPO on 2014-01-31. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Company Info

TVARDI THERAPEUTICS INC

3 Sugar Creek Ctr Blvd, Ste 525

Sugar Land TEXAS US

Employees: 10

TVRD Company Website

TVRD Investor Relations

Phone: 17134898654

TVARDI THERAPEUTICS INC / TVRD FAQ

What is the stock price of TVARDI THERAPEUTICS INC today?

The current stock price of TVRD is 28.76 USD. The price decreased by -2.77% in the last trading session.


What is the ticker symbol for TVARDI THERAPEUTICS INC stock?

The exchange symbol of TVARDI THERAPEUTICS INC is TVRD and it is listed on the Nasdaq exchange.


On which exchange is TVRD stock listed?

TVRD stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for TVARDI THERAPEUTICS INC stock?

13 analysts have analysed TVRD and the average price target is 58.29 USD. This implies a price increase of 102.66% is expected in the next year compared to the current price of 28.76. Check the TVARDI THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is TVARDI THERAPEUTICS INC worth?

TVARDI THERAPEUTICS INC (TVRD) has a market capitalization of 269.77M USD. This makes TVRD a Micro Cap stock.


How many employees does TVARDI THERAPEUTICS INC have?

TVARDI THERAPEUTICS INC (TVRD) currently has 10 employees.


What are the support and resistance levels for TVARDI THERAPEUTICS INC (TVRD) stock?

TVARDI THERAPEUTICS INC (TVRD) has a support level at 24.32 and a resistance level at 30.42. Check the full technical report for a detailed analysis of TVRD support and resistance levels.


Is TVARDI THERAPEUTICS INC (TVRD) expected to grow?

The Revenue of TVARDI THERAPEUTICS INC (TVRD) is expected to decline by -82.49% in the next year. Check the estimates tab for more information on the TVRD EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy TVARDI THERAPEUTICS INC (TVRD) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TVARDI THERAPEUTICS INC (TVRD) stock pay dividends?

TVRD does not pay a dividend.


When does TVARDI THERAPEUTICS INC (TVRD) report earnings?

TVARDI THERAPEUTICS INC (TVRD) will report earnings on 2025-11-12, after the market close.


What is the Price/Earnings (PE) ratio of TVARDI THERAPEUTICS INC (TVRD)?

TVARDI THERAPEUTICS INC (TVRD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-78.48).


What is the Short Interest ratio of TVARDI THERAPEUTICS INC (TVRD) stock?

The outstanding short interest for TVARDI THERAPEUTICS INC (TVRD) is 12.39% of its float. Check the ownership tab for more information on the TVRD short interest.


TVRD Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to TVRD.


Chartmill TA Rating
Chartmill Setup Rating

TVRD Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to TVRD. The financial health of TVRD is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TVRD Financial Highlights

Over the last trailing twelve months TVRD reported a non-GAAP Earnings per Share(EPS) of -78.48. The EPS decreased by -37.11% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -115.7%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%92.49%
Sales Q2Q%-100%
EPS 1Y (TTM)-37.11%
Revenue 1Y (TTM)-49.96%

TVRD Forecast & Estimates

13 analysts have analysed TVRD and the average price target is 58.29 USD. This implies a price increase of 102.66% is expected in the next year compared to the current price of 28.76.

For the next year, analysts expect an EPS growth of 98.33% and a revenue growth -82.49% for TVRD


Analysts
Analysts84.62
Price Target58.29 (102.68%)
EPS Next Y98.33%
Revenue Next Year-82.49%

TVRD Ownership

Ownership
Inst Owners11.11%
Ins Owners25.89%
Short Float %12.39%
Short Ratio12.95